Latest Life Sciences News

Page 1 of 13
Patrys has initiated manufacturing and regulatory steps for RLS-2201, its injectable Quetiapine formulation targeting delirium, aiming for Phase 0 trials in the second half of 2026.
Ada Torres
Ada Torres
11 Mar 2026
Bio-Gene Technology Limited reports strong progress in toxicology studies for Flavocide, targeting its first regulatory submission in Australia by March 2027. This milestone sets the stage for global registrations of the novel insecticide with a new mode of action.
Victor Sage
Victor Sage
3 Mar 2026
Aumake Limited reported a sharp 45% drop in half-year revenue alongside a 24% increase in net loss, while securing new capital and a major distribution deal to support its pivot in the China market.
Logan Eniac
Logan Eniac
27 Feb 2026
Radiopharm Theranostics reported a 44% increase in net loss to $27 million for the half-year ended December 2025, driven by expanded R&D spending. The company bolstered its cash reserves through a $35 million placement while progressing multiple clinical trials across its radiopharmaceutical pipeline.
Ada Torres
Ada Torres
27 Feb 2026
WAM Alternative Assets Limited reported a robust half-year result with net profit surging 40% and declared a 3.0 cents per share interim dividend. The company expanded its private debt exposure and introduced a new treasury solution, underpinning its diversified alternative assets strategy.
Claire Turing
Claire Turing
27 Feb 2026
Bioxyne Limited has reported a remarkable half-year performance, with revenues soaring 149% to $31.3 million and net profit more than doubling to $7.3 million, driven by strong demand for medicinal cannabis, MDMA, and psilocybin products and expanding international operations.
Victor Sage
Victor Sage
26 Feb 2026
Optiscan Imaging reports a sharp 43% drop in revenue and a 43% rise in losses for H1 FY26, driven by restricted research funding in key markets. The company bolsters its balance sheet with a $17.75 million capital raise to advance clinical studies and regulatory approvals.
Ada Torres
Ada Torres
25 Feb 2026
TrivarX Limited reported a $1.26 million half-year loss as it completed the acquisition of Stabl-Im brain imaging IP and validated its mental health screening technology in veterans. The company raised $4.2 million to fund clinical development and expand its diagnostic portfolio.
Ada Torres
Ada Torres
24 Feb 2026
Firebrick Pharma reports a reduced half-year loss of $1.26 million while launching its Nasodine Throat Spray in Singapore and Fiji, with regulatory approval pending in the Philippines.
Ada Torres
Ada Torres
24 Feb 2026
PYC Therapeutics reported a narrowed half-year loss of $22.8 million while progressing four RNA drug candidates through clinical stages. The company announced a major $653 million capital raising to extend its cash runway to 2030 and support ongoing development.
Ada Torres
Ada Torres
23 Feb 2026
EZZ Life Science Holdings has secured a four-year exclusive global distribution agreement with Aumake Limited, committing to at least A$10 million in purchases. This partnership aims to accelerate EZZ’s international reach while preserving brand control.
Victor Sage
Victor Sage
17 Feb 2026
Aumake Limited has secured a four-year exclusive global distribution agreement with EZZ Life Sciences, targeting $10 million in sales and expanding its footprint in high-margin nutraceuticals.
Victor Sage
Victor Sage
17 Feb 2026